6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
What became of romosozumab's fracture benefits after the ARCH trial closed? This deep-dive covers durability data, bone density trajectories, late cardiovascular safety signals, and what sequential therapy evidence tells us about long-term outcomes.
A deep dive into the ARCH trial's primary and secondary endpoints for romosozumab vs alendronate, including effect sizes, confidence intervals, time-course data, and subgroup analyses.
A deep-dive into the ARCH trial (2017), which compared romosozumab to alendronate in postmenopausal women with osteoporosis and prior fracture, showing a 48% reduction in new vertebral fractures.
A critical appraisal of the ARCH trial (romosozumab vs alendronate) covering enrollment biases, cardiovascular safety signals, follow-up gaps, generalizability concerns, and conflict-of-interest disclosures.
A deep-dive into the ARCH trial's design choices, from randomization and blinding to the comparator rationale and statistical framework, and how each decision shapes the clinical interpretation of romosozumab vs alendronate.
How the ARCH trial reshaped osteoporosis treatment sequencing, guideline updates, and real-world prescribing of romosozumab for high-fracture-risk patients.